ArticleESMO open2026

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.

G Curigliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.